Life Sciences

  • December 16, 2025

    Ex-NIAID Director Claims Retaliation in Trump Admin Suit

    The former director of the National Institute of Allergy and Infectious Diseases filed suit in Maryland federal court on Tuesday alleging Trump administration appointees violated her constitutional rights by illegally terminating her employment and that she cannot expect her claims to be fairly heard by the "undermined" U.S. Office of Special Counsel.

  • December 16, 2025

    Samsung Wants ITC To Consider Oura Smart Ring IP Fight

    Samsung has expanded its legal battle with Oura over patents covering biometric-tracking wearable technologies, telling the U.S. International Trade Commission that Oura's smart rings infringe a set of four patents owned by Samsung.

  • December 16, 2025

    PE-Backed Medline Prices Long-Awaited $6.3B IPO

    Private equity-backed medical supplies giant Medline, guided by Simpson Thacher & Bartlett LLP, on Tuesday priced an upsized initial public offering, raising $6.26 billion in what will be the largest IPO of 2025 just weeks before year-end.

  • December 16, 2025

    Ultrahuman Loses Bids To Halt ITC Order In Oura Patent Case

    The U.S. International Trade Commission and the Federal Circuit have both denied requests by Ultrahuman to stay ITC orders barring imports of its smart rings found to infringe an Ouraring patent, turning aside Ultrahuman's arguments that the orders are too broad.

  • December 16, 2025

    DOD To Reevaluate Discharges Over COVID Vax Refusal

    The U.S. Department of Defense said on Tuesday that Secretary of Defense Pete Hegseth ordered a reevaluation of the discharge status of service members who were involuntarily removed from the military after they refused to receive the COVID-19 vaccine. 

  • December 16, 2025

    Vax Skeptics Cite High Court In New Challenge To NY Mandate

    A vaccine skepticism advocacy group once tied to Secretary of Health and Human Services Robert F. Kennedy Jr. is revamping its fight against New York's school vaccination mandate, arguing recent activity by the U.S. Supreme Court necessitates a fresh analysis.

  • December 16, 2025

    PTAB Cuts X-Ray Patent Claims After Fed. Circ. Remand

    The Patent Trial and Appeal Board has found that three claims that Sigray Inc. challenged in a Carl Zeiss X-Ray Microscopy Inc. X-ray imaging patent were invalid after the Federal Circuit told it to take another look at the claims.

  • December 16, 2025

    Va. Judge Advances Most Claims In Stelara Antitrust Case

    A Virginia federal judge has allowed health insurer CareFirst's anticompetition and patent fraud claims against Johnson & Johnson to move forward in a case alleging anticompetitive behavior in relation to the immunosuppressive drug Stelara, while letting the pharmaceutical giant escape some claims of misrepresentation.

  • December 16, 2025

    Trump Executive Order Calls Fentanyl A 'WMD'

    President Donald Trump has declared fentanyl a "weapon of mass destruction," according to an executive order that explicitly calls on the military to respond to "chemical incidents in the homeland."

  • December 16, 2025

    The Most Important Healthcare And Life Science Deals Of 2025

    Attorneys taking stock of 2025 spoke to Law360 about the most important deals of the year, including Pfizer’s high-profile acquisition of Metsera and transactions in outpatient services and gene therapy.

  • December 16, 2025

    Trends That Shaped Healthcare Dealmaking In 2025

    With 2025 coming to a close, Law360 Healthcare Authority asked attorneys focused on healthcare deals for their take on the trends that influenced dealmaking over the last 12 months.

  • December 16, 2025

    Merck Sued Over Time Rounding, OT Averaging At NC Plant

    A Merck manufacturing facility in North Carolina rounded workers' time to short them on pay, averaged out overtime across two weeks and fired an operator technician because of his sleep apnea, the worker told a federal court in a proposed class and collective action against the pharmaceutical giant.

  • December 16, 2025

    Jury Says Magnolia Medical Is Owed $1.6M After Patent Trial

    A Delaware federal jury on Tuesday morning found that Magnolia Medical Technologies Inc. is entitled to nearly $1.6 million after Kurin Inc. infringed its patents tied to devices meant for drawing blood.

  • December 16, 2025

    5 Big Litigation Developments Out Of Georgia In 2025

    It was a busy year for courts in Georgia, with a federal judge ordering the state's corrections system to continue providing hormone therapy to transgender people in prison, and prosecutors deciding to drop the historic racketeering case against President Donald Trump and his allies. Here, Law360 recaps the biggest legal developments to come out of Peach State courts in 2025.

  • December 16, 2025

    Another Dechert IP Atty Leaves, This Time For Morgan Lewis

    Morgan Lewis LLP has added another departing member of the Dechert LLP intellectual property team, who joins the firm in Boston after Dechert's global intellectual property practice co-chair, two partners, and a total of 30 professionals moved to Cooley LLP last week.

  • December 16, 2025

    Medical Device Maker Zynex Hits Ch. 11 With Sale Plans

    Zynex Inc., a pain management medical device maker, filed for bankruptcy protection in Texas with at least $66.7 million in debt and plans to sell the business backed by a stalking horse bid from its creditors.

  • December 15, 2025

    Smartwatch Giants Sued Over Fall Detection Patents

    A company that makes medical alert watches for the elderly has sued Apple, Samsung, Google and Garmin in federal court and the U.S. International Trade Commission, alleging that the fall detection features in their smartwatches infringe two patents.

  • December 15, 2025

    States Fight Sandoz Bid To Argue Duplication In Generics Row

    Multiple attorneys general have told a Connecticut federal court that Sandoz Inc. and Fougera Pharmaceuticals Inc. can't claim the states' grievances over allegations of price fixing are duplicative of claims that were already settled, since there are some claims and forms of relief that only state plaintiffs can seek.

  • December 15, 2025

    DOJ Raises Accreditation Concerns In Vet School Case

    The U.S. Department of Justice waded into a Tennessee veterinary school's antitrust case challenging the American Veterinary Medical Association's accreditation requirements, raising concerns about the risk posed by professional groups that play gatekeeping functions.

  • December 15, 2025

    Ohio Gov. To Designate Synthetic Kratom Extract Illegal Drug

    Ohio Gov. Mike DeWine is looking to immediately ban synthetic kratom compounds while simultaneously seeking to either ban or heavily regulate the active ingredient in "natural kratom," citing serious public health concerns.

  • December 15, 2025

    Formula Suits An 'Undue Burden' On Cook County, Panel Says

    An Illinois appellate court Friday agreed with Abbott Laboratories that 23 lawsuits alleging the company failed to warn of important risks associated with infant formulas and caused premature babies to develop necrotizing enterocolitis should not have been filed in Cook County, where the infants at the center of those cases were not born and have never lived.

  • December 15, 2025

    USPTO Replaces Denver Office With Center In Montana

    Montana has been picked by the U.S. Patent and Trademark Office to be the first state to oversee community outreach in the area formerly serviced by the now-shuttered Rocky Mountain Regional Outreach Office in Denver.

  • December 15, 2025

    Cencora Pays $5B For Majority Stake Of OneOncology

    Pharmaceutical company Cencora Inc. unveiled plans Monday to acquire a majority stake in cancer care company OneOncology for $5 billion, buying interest from private equity shop TPG in a deal built by three law firms.

  • December 15, 2025

    Connecticut 'Likely' To Settle Generic Drug Price Cap Dispute

    A pharmaceutical industry trade group and the state of Connecticut have signaled their intent to settle a feud over the interpretation of the state's generic drug price cap law, and a federal judge gave them until Monday to say more about their plan.

  • December 15, 2025

    Fed. Circ. Won't Revive Bard Patents In AngioDynamics Row

    The Federal Circuit on Monday refused to revive claims in C.R. Bard patents on implanted catheter receptacles that were challenged by AngioDynamics, backing a Delaware federal court's finding that the claims were anticipated.

Expert Analysis

  • Defeating Estoppel-Based Claims In Legal Malpractice Actions

    Author Photo

    State supreme court cases from recent years have addressed whether positions taken by attorneys in an underlying lawsuit can be used against them in a subsequent legal malpractice action, providing a foundation to defeat ex-clients’ estoppel claims, says Christopher Blazejewski at Sherin and Lodgen.

  • Trade Secret Rulings Reveal The Cost Of Poor Preparation

    Author Photo

    Two recent federal appellate decisions show that companies must be prepared to prove their trade secrets with specificity, highlighting how an asset management program that identifies key confidential information before litigation arises can provide the clarity and documentation that courts increasingly require, say attorneys at Mintz.

  • Series

    The Biz Court Digest: How It Works In Massachusetts

    Author Photo

    Since its founding in 2000, the Massachusetts Business Litigation Session's expertise, procedural flexibility and litigant-friendly case management practices have contributed to the development of a robust body of commercial jurisprudence, say James Donnelly at Mirick O’Connell, Felicia Ellsworth at WilmerHale and Lisa Wood at Foley Hoag.

  • Why Appellees Should Write Their Answering Brief First

    Author Photo

    Though counterintuitive, appellees should consider writing their answering briefs before they’ve ever seen their opponent’s opening brief, as this practice confers numerous benefits related to argument structure, time pressures and workflow, says Joshua Sohn at the U.S. Department of Justice.

  • Navigating DEA Quotas: Key To Psychedelics Industry Growth

    Author Photo

    As new compounds like DOI enter the Schedule I landscape, manufacturers who anticipate U.S. Drug Enforcement Administration quota regulations, and build quota management into their broader strategy, will be best equipped to meet the growing demand, say Kimberly Chew at Husch Blackwell and Jaime Dwight at Promega.

  • Series

    Mindfulness Meditation Makes Me A Better Lawyer

    Author Photo

    Mindful meditation enables me to drop the ego, and in helping me to keep sight of what’s important, permits me to learn from the other side and become a reliable counselor, says Roy Wyman at Bass Berry.

  • Growth, Harmonization In Focus As Hague System Turns 100

    Author Photo

    One hundred years after its establishment, the Hague System has grown into an important pillar of international design protection, offering a promising path toward even greater harmonization in design law as its geographic reach continues to expand, say attorneys at Sterne Kessler.

  • Lessons From 7th Circ. Decision Affirming $183M FCA Verdict

    Author Photo

    The Seventh Circuit's decision to uphold a $183 million False Claims Act award against Eli Lilly engages substantively with recurring materiality and scienter questions and provides insights into appellate review of complex trial court judgments, say Ellen London at London & Naor, Li Yu at Bernstein Litowitz and Kimberly Friday at Osborn Maledon.

  • Opinion

    Punitive Damages Awards Should Be Limited To 1st Instance

    Author Photo

    Recent verdicts in different cases against Johnson & Johnson and Monsanto showcase a trend of multiple punitive damages being awarded to different plaintiffs for the same course of conduct by a single defendant, a practice that should be deemed unconstitutional by the U.S. Supreme Court, says Jacob Mihm at Polales Horton.

  • How Calif. High Court Is Rethinking Forum Selection Clauses

    Author Photo

    Two recent cases before the California Supreme Court show that the state is shifting toward greater enforcement of freely negotiated forum selection clauses between sophisticated parties, so litigators need to revisit old assumptions about the breadth of California's public policy exception, says Josh Patashnik at Perkins Coie.

  • AI Litigation Tools Can Enhance Case Assessment, Strategy

    Author Photo

    Civil litigators can use artificial intelligence tools to strengthen case assessment and aid in early strategy development, as long as they address the risks and ethical considerations that accompany these uses, say attorneys at Barnes & Thornburg.

  • Attys Beware: Generative AI Can Also Hallucinate Metadata

    Author Photo

    In addition to the well-known problem of AI-generated hallucinations in legal documents, AI tools can also hallucinate metadata — threatening the integrity of discovery, the reliability of evidence and the ability to definitively identify the provenance of electronic documents, say attorneys at Law & Forensics.

  • Lessons From Fed. Circ. On Expert Testimony In Patent Cases

    Author Photo

    Several recent decisions from the Federal Circuit are notable for their treatment of expert testimony, with relevance to the three pillars of every patent case — infringement, invalidity and damages — and offer lessons on ensuring that expert testimony is both admissible and sufficient to support the jury's verdict, say attorneys at Honigman.

  • When Atty Ethics Violations Give Rise To Causes Of Action

    Author Photo

    Though the Model Rules of Professional Conduct make clear that a violation of the rules does not automatically create a cause of action, attorneys should beware of a few scenarios in which they could face lawsuits for ethical lapses, says Brian Faughnan at Faughnan Law.

  • What's New In FDA's Latest Cell And Gene Therapy Guidance

    Author Photo

    New draft guidance from the U.S. Food and Drug Administration, along with other recent initiatives, come together to promote cell and gene therapy product development by streamlining development and review pathways, say attorneys at Holland & Knight.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.